ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media


 
    Global biotech news service, BioWorld, in its Other News To Note, covered Noxopharm's reporting (11 Aug 2020) that, " Independent research published in European Urology Oncology showed the combination of 177Lu-PSMA-617 radioligand therapy and Veyond  
 
    August 19, 2020 US Life Science website, Clinical Research News, said Noxopharm had announced new research showing Veyonda(r) cancer survival rates in a peer-reviewed publication, European Urology Oncology, the first official publication of the Euro  
 
    Pharmaceutical news digital site, FirstWord Pharma, continued coverage on Noxopharm's lead drug candidate, Veyonda(r)'s trials in late -stage prostate cancer.  
 
    PharmaVOICE.com provided the news release, "Noxopharm Announces New Research Showing Veyonda(r) Cancer Survival Rates" which reported that the Australian clinical-stage drug development company announced the publication of the first manuscript of the  
 
    Life Sciences digital hub, BioSpace, reported on Noxopharm's announcement (11 August 2020) regarding the details of the peer-reviewed publication of key LuPIN (Phase 2) study data in its ongoing late-stage prostate cancer trial.  
 
    US website Clinical Research News reported on Noxopharm's pre-clinical announcement concerning idronoxil's ability to convert 'cold' cancer tumours to 'hot' ones in the laboratory.  
 
    BioWorld notes in its section Other News to Note for July 23,2020, "Noxopharm Ltd reported preclinical data from two independent research groups confirming that idronoxil, the active ingredient in the company's immuno-oncology drug candidate......  
 
    US online forum BioSpace reports Noxopharm's announcement, " Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting 'Cold' Tumors to 'Hot'  
 
    US publication Clinical Research News: the Industry Updates section mentions Noxopharm's planned COVID-19 trial using Veyonda®  
 
    Genetic Engineering and Biotechnology News (GEN): reports on Noxopharm's Veyonda® as a potential COVID-19 treatment candidate, noting it as a cGAS-STING signaling pathway inhibitor designed to treat the cytokine storm and septic shock associated  
 
    CenterWatch Weekly notes in its COVID-19 Drug Research Roundup - Therapeutics : Noxopharm has begun planning a phase 1 trial of its investigational oncology drug Veyonda(NOX66) in Europe  
 
    In more industry news, Pharmaceutical Business Review (UK) highlighted that Noxopharm reports its COVID-19 trial programme planned to commence a Phase 1 trial in Europe  
 
    US biotech publication BioWorld highlights Noxopharm’s idronoxil’s ability to block the STING pathway in a potential treatment in the fight against COVID-19  
 
    Drug Delivery and Development: EXECUTIVE INTERVIEW - Noxopharm: Introducing a Novel & Potentially Transformative Drug Candidate in the Treatment of Cancer  
 
    BiotechDispatch: Noxopharm Confirms Veyonda Presentation at Two Conferences  

Noxopharm announcement that scientific data from DARRT-1 and LuPIN prostate cancer treatment studies included in two major oncology conferences this year, as covered by Biotech Dispatch

 
    Veyonda® Research at Major Oncology Conferences  

Australian drug development company Noxopharm™ to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas

 
    Healthcare Tech Outlook: Veyonda with Radiotherapy Provides Anti-Cancer Treatment  

US digital medical magazine Healthcare Tech Outlook profiling the enhancing effect of Veyonda on radiotherapy seen in pre-clinical trials and in clinical trials with men with prostate cancer.

 
    Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment - Further Promising Results  

Video: CEO Dr Greg van Wyk discusses anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.

 
    Biotech Dispatch: Sydney-based Noxopharm looking to make 'cold' tumours 'hot'  

Independent news service, Biotech Dispatch interviews Noxopharm Founder and Exec Chairman Dr Graham Kelly on Veyonda's effect on cancer cells and the immune system.

 
    Dot Med: New combination therapy established as safe and effective for prostate cancer  
 
    News Medical: Novel combination therapy shown to be safe and effective for prostate cancer patients  
 
    Radiology Business: A new treatment option for prostate cancer patients  
 
    SNMMI: Press Release—Society of Nuclear Medicine and Molecular Imaging  
 
    UPI: A new combination therapy has shown promise in effectively fighting prostate cancer, new research shows  
 
    Drug Discovery News May 2019 : A booster for immuno-oncology drugs  
 
    From Academia To Pharma CEO: Challenges And Lessons Learned – Dr Graham Kelly Noxopharm Executive Chairman and Founder  
 
    Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney  
 
    Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials  
 
    Noxopharm’s collaboration finds drug to help stroke victims  
 
    AFR Feature : Innovations in Stroke Therapy  
 
    New Investor - Shed Connect: Hidden Gems in the Small Caps Space  
 
    Shed Connect - The Rub: Noxopharm Prepares for Clinical Trials  
 
    St Vincent's Hospital Sydney Prostate Cancer Study  
 
    AFR editorial : Innovations In Cancer Research  
 
    UNSW Newsroom: Working with Noxopharm to prevent traumatic head injury